Literature DB >> 10426843

Ventricular remodeling in active myocarditis. Myocarditis Treatment Trial.

L A Mendes1, M H Picard, G W Dec, V L Hartz, I F Palacios, R Davidoff.   

Abstract

BACKGROUND: Remodeling of the left ventricle with the development of a spherical cavity occurs in dilated cardiomyopathy and is associated with a poor long-term prognosis. The early effects of myocarditis on left ventricular geometry have not been previously described or correlated with clinical outcome.
METHODS: The baseline echocardiograms of 35 patients with biopsy-confirmed myocarditis were compared with 20 normal controls. Left ventricular end-diastolic volume, long axis length, and mid-cavity diameter were measured. The degree of sphericity was expressed as the ratio of the mid-cavity diameter to the long axis length. Left ventricular ejection fraction was assessed by radionuclide angiography.
RESULTS: In patients with myocarditis, mean left ventricular volume of 81 +/- 29 mL/m(2) was significantly greater than 50 +/- 8 mL/m(2) in controls (P =.001). Chamber dilatation occurred primarily along the mid-cavity diameter, which measured 5.3 +/- 0.8 cm in patients with myocarditis versus 4.2 +/- 0.4 cm in controls (P =.001). The degree of left ventricular sphericity in patients with myocarditis, 0.64 +/- 0.08, was significantly greater than that of controls, 0.54 +/- 0.04 (P =.001). When patients were stratified according to left ventricular volume, patients with increased left ventricular volume (>75 mL/m(2)) were associated with a more spherical chamber and lower left ventricular ejection fraction than patients with a more normal left ventricular volume (</=75 mL/m(2)).
CONCLUSIONS: Active myocarditis is associated with early left ventricular remodeling and the development of a spherical chamber. These changes correlate with ventricular dilatation and reduced left ventricular ejection fraction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426843     DOI: 10.1016/s0002-8703(99)70116-x

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Authors:  Marc P Bonaca; Benjamin A Olenchock; Joe-Elie Salem; Stephen D Wiviott; Stephane Ederhy; Ariel Cohen; Garrick C Stewart; Toni K Choueiri; Marcelo Di Carli; Yves Allenbach; Dharam J Kumbhani; Lucie Heinzerling; Laleh Amiri-Kordestani; Alexander R Lyon; Paaladinesh Thavendiranathan; Robert Padera; Andrew Lichtman; Peter P Liu; Douglas B Johnson; Javid Moslehi
Journal:  Circulation       Date:  2019-07-02       Impact factor: 29.690

2.  Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis.

Authors:  Yan Shen; Wei Xu; Yi-Wei Chu; Ying Wang; Quan-Sheng Liu; Si-Dong Xiong
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 3.  Cardiac imaging techniques for the assessment of immune checkpoint inhibitor-induced cardiotoxicity and their potential clinical applications.

Authors:  Yi Li; Pei-Jun Liu; Zhuo-Li Zhang; Yi-Ning Wang
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

4.  FR167653 suppresses the progression of experimental autoimmune myocarditis.

Authors:  Seitaro Maruyama; Kiminori Kato; Makoto Kodama; Yuji Okura; Satoru Hirono; Koichi Fuse; Haruo Hanawa; Osamu Nakagawa; Mikio Nakazawa; Takashi Miida; Eisin Yaoita; Tadashi Yamamoto; Ikuo Inoue; Yoshifusa Aizawa
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

Review 5.  Diagnosis and treatment of viral myocarditis.

Authors:  Jason C Schultz; Anthony A Hilliard; Leslie T Cooper; Charanjit S Rihal
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 6.  Myocarditis.

Authors:  Leslie T Cooper
Journal:  N Engl J Med       Date:  2009-04-09       Impact factor: 91.245

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.